Identifying Biomarkers in Alzheimer's Disease

Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 9, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to detect Alzheimer’s disease (AD) early, which is important because there is currently no cure for this serious brain condition. The researchers are studying specific markers in the blood, eye scans, and brain imaging techniques to see if they can improve how we identify and understand the stages of Alzheimer’s. This research is particularly looking at the local Chinese population and aims to help doctors diagnose the disease before it progresses to more severe stages.

To participate in this study, individuals need to be of Chinese ethnicity and have a clinical diagnosis of "probable Alzheimer's disease" if they are part of the dementia group. People with other types of dementia or those who cannot undergo certain imaging tests will not be eligible. Participants can expect to undergo various tests and imaging procedures to help the researchers gather valuable information that could lead to better early detection of Alzheimer’s in the future. This trial is currently recruiting participants of all ages, and it plays a crucial role in addressing a growing public health concern as the number of people affected by Alzheimer’s is expected to rise significantly in the coming years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chinese ethnicity
• • \[For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)
• Exclusion Criteria:
• • Clinical diagnosis of non-AD dementia
• • contraindication for MRI or PET